These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26159559)

  • 21. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography.
    Kim YK; Kwak HS; Han YM; Kim CS
    J Comput Assist Tomogr; 2007; 31(5):702-11. PubMed ID: 17895780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT.
    Akai H; Kiryu S; Matsuda I; Satou J; Takao H; Tajima T; Watanabe Y; Imamura H; Kokudo N; Akahane M; Ohtomo K
    Eur J Radiol; 2011 Nov; 80(2):310-5. PubMed ID: 20732773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of gadoxetic acid-enhanced dynamic MR imaging and contrast-enhanced computed tomography for preoperative evaluation of colorectal liver metastases.
    Asato N; Tsurusaki M; Sofue K; Hieda Y; Katsube T; Kitajima K; Murakami T
    Jpn J Radiol; 2017 Apr; 35(4):197-205. PubMed ID: 28251499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.
    Ahn SS; Kim MJ; Lim JS; Hong HS; Chung YE; Choi JY
    Radiology; 2010 May; 255(2):459-66. PubMed ID: 20413759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of small hepatocellular carcinoma: intraindividual comparison of gadoxetic acid-enhanced MRI at 3.0 and 1.5 T.
    Kim YK; Kim CS; Han YM; Yu HC; Choi D
    Invest Radiol; 2011 Jun; 46(6):383-9. PubMed ID: 21467946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns.
    Park MJ; Kim YK; Lee MW; Lee WJ; Kim YS; Kim SH; Choi D; Rhim H
    Radiology; 2012 Sep; 264(3):761-70. PubMed ID: 22843769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma.
    Kim YK; Kim CS; Chung GH; Han YM; Lee SY; Chon SB; Lee JM
    AJR Am J Roentgenol; 2006 Jan; 186(1):149-57. PubMed ID: 16357395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
    Jang KM; Kim SH; Kim YK; Choi D
    Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine.
    Park G; Kim YK; Kim CS; Yu HC; Hwang SB
    Br J Radiol; 2010 Dec; 83(996):1010-6. PubMed ID: 20682591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of liver metastases: Gadoxetic acid-enhanced three-dimensional MR imaging versus ferucarbotran-enhanced MR imaging.
    Kim YK; Lee YH; Kwak HS; Kim CS; Han YM
    Eur J Radiol; 2010 Jan; 73(1):131-6. PubMed ID: 18996659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging.
    Haradome H; Grazioli L; Tinti R; Morone M; Motosugi U; Sano K; Ichikawa T; Kwee TC; Colagrande S
    J Magn Reson Imaging; 2011 Jul; 34(1):69-78. PubMed ID: 21598343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT.
    Park VY; Choi JY; Chung YE; Kim H; Park MS; Lim JS; Kim KW; Kim MJ
    Liver Int; 2014 Nov; 34(10):1593-602. PubMed ID: 24673802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late, and whole triple arterial phase imaging.
    Mori K; Yoshioka H; Takahashi N; Yamaguchi M; Ueno T; Yamaki T; Saida Y
    AJR Am J Roentgenol; 2005 Jan; 184(1):63-9. PubMed ID: 15615952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The capsule appearance of hepatocellular carcinoma in gadoxetic acid-enhanced MR imaging: Correlation with pathology and dynamic CT.
    Kim B; Lee JH; Kim JK; Kim HJ; Kim YB; Lee D
    Medicine (Baltimore); 2018 Jun; 97(25):e11142. PubMed ID: 29924016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging.
    Hwang J; Kim YK; Kim JM; Lee WJ; Choi D; Hong SS
    Liver Transpl; 2014 Dec; 20(12):1436-46. PubMed ID: 25103727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
    Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
    Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.